China Resources Double-Crane Wholly Owned Subsidiary Obtains Drug Registration Certificate for Progesterone Soft Capsules

CLS··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

China Resources Double-Crane announced that its wholly owned subsidiary, Shanxi Jinxin Double-Crane Pharmaceutical, has received the Drug Registration Certificate for Progesterone Soft Capsules from the National Medical Products Administration. The drug is indicated for the treatment of functional disorders caused by progesterone deficiency and is deemed to have passed the consistency evaluation. As of the announcement date, the company has invested a cumulative 17.2675 million yuan in research and development.

Impact on assets 2

Others▲ · 2 stocks

Off-coverage companies 1

Shanxi Jinxin Shuanghe Pharmaceutical Co LtdPrivate▲ Positive
Technologyrelevance

As the subsidiary that received the drug registration certificate, directly benefits from the approval.

© 2026 MarketIVNews